文献

J-GLOBAL ID：202002238958976517   整理番号：20A2059668

ウイルス感染性と抗原性に対するSARS-CoV-2スパイクにおける突然変異の影響【JST・京大機械翻訳】

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

著者 (22件)： Li Qianqian (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Li Qianqian (Graduate School of Peking Union Medical College, No. 9 Dongdan Santiao, Dongcheng District, Beijing 100730, China) ,  Wu Jiajing (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Nie Jianhui (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Zhang Li (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Hao Huan (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Liu Shuo (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Zhao Chenyan (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Zhang Qi (Center for Global Health and Infectious Diseases, Comprehensive AIDS Research Center, and Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing 100084, China) ,  Liu Huan (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Nie Lingling (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Qin Haiyang (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Wang Meng (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Lu Qiong (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Li Xiaoyu (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Sun Qiyu (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Liu Junkai (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Zhang Linqi (Center for Global Health and Infectious Diseases, Comprehensive AIDS Research Center, and Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing 100084, China) ,  Li Xuguang (Centre for Vaccine Evaluation, Biologics and Genetic Therapies Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada) ,  Huang Weijin (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Wang Youchun (Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, C...) ,  Wang Youchun (Graduate School of Peking Union Medical College, No. 9 Dongdan Santiao, Dongcheng District, Beijing 100730, China)
資料名： Cell (Cambridge, Mass.)  (Cell (Cambridge, Mass.))
巻： 182  号： 5  ページ： 1284-1294.e9  発行年： 2020年 
JST資料番号： A0707B  ISSN： 0092-8674  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： SARS-CoV-2のスパイク蛋白質は変異を受け,高度にグリコシル化されている。これらの変異の生物学的意義を調べることは非常に重要である。ここでは,回復性患者由来の中和抗体および血清のパネルに対する感染性および反応性に対する80の変異体および26のグリコシル化部位修飾を検討した。D614Gと他のアミノ酸変化の両方を含むいくつかの変異体と共にD614Gは,有意に感染性であった。受容体結合ドメインでアミノ酸変化を有するほとんどの変異体は感染性が低かったが,A475V,L452R,V483A,およびF490Lを含む変異体はいくつかの中和抗体に耐性になった。さらに,グリコシル化欠失の大部分は感染性が少なく,一方N331とN343グリコシル化の欠失は感染性を劇的に減少させ,ウイルス感染性に対するグリコシル化の重要性を明らかにした。興味深いことに,N234Qは中和抗体に対して顕著に耐性であったが,N165Qはより感受性になった。これらの知見はワクチンと治療抗体の開発において価値がある。Copyright 2020 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： アミノ酸 ,  *ウイルス感染 ,  血清 ,  受容体 ,  *突然変異 ,  ワクチン ,  結合部位 ,  *免疫原性 ,  グリコシル化 ,  中和抗体 ,  スパイク蛋白質 ,  SARSコロナウイルス ,  抗体医薬品
準シソーラス用語： SARSウイルス ,  *重症急性呼吸器症候群 ,  抗体医薬 ,  感染性 , 【Automatic Indexing@JST】

著者キーワード (7件)： COVID-19 ,  SARS-CoV-2 ,  スパイク ,  変異体 ,  変異体 ,  グリコシル化 ,  偽型ウイルス

分類 (2件)： ウイルス感染の生理と病原性  (EG04042Y) ,  感染症・寄生虫症一般  (GD01010H)

タイトルに関連する用語 (5件)： ウイルス感染 ,  抗原性 ,  SARS-CoV-2 ,  スパイク ,  突然変異